Proceeds will fund repurchases of 2028 notes and shares, with an option for an additional $41.25 million.
NeoGenomics priced $275 million in 0.75% convertible senior notes maturing in 2032. The offering includes an option for initial purchasers to acquire up to an additional $41.25 million in notes.
The company plans to use proceeds to repurchase its 2028 convertible notes and shares. No prior comparable offering was disclosed in recent filings.
Shares of NeoGenomics (NASDAQ: NEO) were inactive in after-hours trading following the announcement.